Mural Oncology (NASDAQ:MURA) Shares Up 1.4% – Here’s Why

Mural Oncology plc (NASDAQ:MURA)’s stock price shot up 1.4% during trading on Friday . The stock traded as high as $3.64 and last traded at $3.62. 50,098 shares changed hands during trading, a decline of 69% from the average session volume of 162,563 shares. The stock had previously closed at $3.57.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Price Performance

The company has a market cap of $61.61 million, a P/E ratio of -0.40 and a beta of 3.64. The company has a fifty day simple moving average of $3.82 and a 200-day simple moving average of $3.58.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Commerce Bank bought a new position in shares of Mural Oncology in the third quarter valued at $39,000. FMR LLC grew its position in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares in the last quarter. Jane Street Group LLC purchased a new position in Mural Oncology during the 4th quarter worth approximately $68,000. Two Sigma Advisers LP purchased a new position in Mural Oncology during the 4th quarter worth approximately $84,000. Finally, Bridgeway Capital Management LLC purchased a new position in Mural Oncology during the 4th quarter worth approximately $94,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.